{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:02:18Z","timestamp":1788836538941,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,26]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>In patients receiving immune checkpoint inhibitors, subclinical inflammatory bowel disease can be unmasked, leading to severe colitis. Ulcerative colitis, in particular, may remain undetected when initial symptoms are mild. This report describes a patient with metastatic melanoma whose previously unrecognized ulcerative colitis flared severely after initiating nivolumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 35-year-old man presented with chronic mild diarrhea, persisting for several months, which was initially overlooked. Three months after starting nivolumab therapy, he developed frequent diarrhea and hematochezia that required hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Sigmoidoscopy demonstrated ulcerations with bleeding in the rectosigmoid junction and rectum. Histopathology revealed crypt architectural distortion and inflammatory infiltrates, consistent with ulcerative colitis. Infectious etiologies were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>High-dose intravenous corticosteroids were administered, followed by an oral steroid taper and 5-aminosalicylic acid. Nivolumab was briefly held during acute exacerbations but was ultimately resumed to continue melanoma management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Two months after resuming nivolumab, the patient experienced a diffuse ulcerative colitis flare, now involving the entire colon. A second course of high-dose pulse steroid therapy was initiated, and a further hold on nivolumab is currently under consideration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Mild ulcerative colitis can be unmasked and exacerbated by immune checkpoint inhibitors such as nivolumab, emphasizing the importance of early evaluation for inflammatory bowel disease in patients with persistent diarrhea.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044833","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:02:25Z","timestamp":1759248145000},"page":"e44833","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Exacerbation of previously undetected ulcerative colitis in a patient undergoing nivolumab for metastatic melanoma: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Je-Seong","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School, Hwasun, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-June","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School, Hwasun, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Eun","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School, Hwasun, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Muk","family":"Im","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School, Hwasun, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0551-5954","authenticated-orcid":false,"given":"Joo Yeon","family":"Koo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-495X","authenticated-orcid":false,"given":"Hyung-Hoon","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School, Hwasun, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0422-2439","authenticated-orcid":false,"given":"Young-Eun","family":"Joo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School, Hwasun, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260602","doi-asserted-by":"crossref","first-page":"961805","DOI":"10.3389\/fimmu.2022.961805","article-title":"Clinical cancer immunotherapy: current progress and prospects.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R2-20260602","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20260602","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"R4-20260602","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20260602","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease.","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"},{"key":"R6-20260602","first-page":"e25437","article-title":"Refractory fulminant colitis requiring surgical intervention in a patient with ulcerative colitis on atezolizumab therapy for small cell lung cancer: an atypical case.","volume":"14","author":"Steiger","year":"2022","journal-title":"Cureus"},{"key":"R7-20260602","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gastha.2024.05.011","article-title":"Histopathologic features of unmasked inflammatory bowel disease following immune checkpoint inhibitor therapy in colon biopsies.","volume":"3","author":"Zhang","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"R8-20260602","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","article-title":"Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective.","volume":"71","author":"Karamchandani","year":"2018","journal-title":"J Clin Pathol"},{"key":"R9-20260602","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAS.0000000000001730","article-title":"Histopathology of gastrointestinal immune-related adverse events: a practical review for the practicing pathologist.","volume":"46","author":"Zhang","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R10-20260602","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract.","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"key":"R11-20260602","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/medicina60091422","article-title":"Atezolizumab-induced ulcerative colitis in patient with hepatocellular carcinoma: case report and literature review.","volume":"60","author":"Kim","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"R12-20260602","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12328-020-01276-4","article-title":"Collagenous colitis and atezolizumab therapy: an atypical case.","volume":"14","author":"Gallo","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"R13-20260602","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: a comprehensive review.","volume":"7","author":"Som","year":"2019","journal-title":"World J Clin Cases"},{"key":"R14-20260602","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"R15-20260602","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jcb.240560110","article-title":"Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.","volume":"56","author":"Lejeune","year":"1994","journal-title":"J Cell Biochem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:01:46Z","timestamp":1780423306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":15,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044833","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"2025-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}